These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 2146067)
1. Different absorption of isophane (NPH) insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique. Thow JC; Johnson AB; Fulcher G; Home PD Diabet Med; 1990 Aug; 7(7):600-2. PubMed ID: 2146067 [TBL] [Abstract][Full Text] [Related]
2. Morphology of palpably abnormal injection sites and effects on absorption of isophane(NPH) insulin. Thow JC; Johnson AB; Marsden S; Taylor R; Home PD Diabet Med; 1990 Nov; 7(9):795-9. PubMed ID: 2148131 [TBL] [Abstract][Full Text] [Related]
3. Absorption of NPH (isophane) insulin in resting diabetic patients: evidence for subcutaneous injection in the thigh as the preferred site. Henriksen JE; Vaag A; Hansen IR; Lauritzen M; Djurhuus MS; Beck-Nielsen H Diabet Med; 1991 Jun; 8(5):453-7. PubMed ID: 1830531 [TBL] [Abstract][Full Text] [Related]
4. Exercise augments the absorption of isophane (NPH) insulin. Thow JC; Johnson AB; Antsiferov M; Home PD Diabet Med; 1989; 6(4):342-5. PubMed ID: 2524341 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018 [TBL] [Abstract][Full Text] [Related]
6. Effect of raising injection-site skin temperature on isophane (NPH) insulin crystal dissociation. Thow JC; Johnson AB; Antsiferov M; Home PD Diabetes Care; 1989 Jun; 12(6):432-4. PubMed ID: 2659303 [TBL] [Abstract][Full Text] [Related]
7. Variation in absorption of NPH insulin due to intramuscular injection. Vaag A; Handberg A; Lauritzen M; Henriksen JE; Pedersen KD; Beck-Nielsen H Diabetes Care; 1990 Jan; 13(1):74-6. PubMed ID: 2404719 [TBL] [Abstract][Full Text] [Related]
8. Glucodynamics and pharmacokinetics of 70/30 vs. 50/50 NPH/regular insulin mixtures after subcutaneous injection. Krug EI; DeRiso L; Tedesco MB; Rao H; Korytkowski MT Diabetes Care; 2001 Sep; 24(9):1694-5. PubMed ID: 11522727 [No Abstract] [Full Text] [Related]
9. Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. Lucidi P; Porcellati F; Marinelli Andreoli A; Carriero I; Candeloro P; Cioli P; Bolli GB; Fanelli CG Diabetes Care; 2015 Dec; 38(12):2204-10. PubMed ID: 26358287 [TBL] [Abstract][Full Text] [Related]
10. The contribution of intermediate-acting insulin preparations to daytime insulin treatment. Robert JJ; Chevenne D; Debray M Diabet Med; 1989 Aug; 6(6):531-6. PubMed ID: 2527136 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Owens DR; Coates PA; Luzio SD; Tinbergen JP; Kurzhals R Diabetes Care; 2000 Jun; 23(6):813-9. PubMed ID: 10841002 [TBL] [Abstract][Full Text] [Related]
12. Absorption kinetics of regular, isophane, and protamine zinc insulin in normal cats. Wallace MS; Peterson ME; Nichols CE Domest Anim Endocrinol; 1990 Oct; 7(4):509-15. PubMed ID: 2261761 [TBL] [Abstract][Full Text] [Related]
13. Bioequivalence of Jusline following subcutaneous administration in healthy subjects. Al-Rubeaan KA; Al-Daghri NM; Alkharfy KM; Al-Attas OS; Hanif FS; Metias NS; Sabico SL Int J Clin Pharmacol Ther; 2008 Jul; 46(7):382-8. PubMed ID: 18793592 [TBL] [Abstract][Full Text] [Related]
14. Absorption kinetics of regular and isophane (NPH) insulin in the normal dog. Goeders LA; Esposito LA; Peterson ME Domest Anim Endocrinol; 1987 Jan; 4(1):43-50. PubMed ID: 3333933 [TBL] [Abstract][Full Text] [Related]
15. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Heinemann L; Linkeschova R; Rave K; Hompesch B; Sedlak M; Heise T Diabetes Care; 2000 May; 23(5):644-9. PubMed ID: 10834424 [TBL] [Abstract][Full Text] [Related]
16. Study of porcine and human isophane (NPH) insulins in normal subjects. Owens DR; Jones IR; Birtwell AJ; Burge CT; Luzio S; Davies CJ; Heyburn P; Heding LG Diabetologia; 1984 Apr; 26(4):261-5. PubMed ID: 6376233 [TBL] [Abstract][Full Text] [Related]
17. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. Joseph SE; Korzon-Burakowska A; Woodworth JR; Evans M; Hopkins D; Janes JM; Amiel SA Diabetes Care; 1998 Dec; 21(12):2098-102. PubMed ID: 9839100 [TBL] [Abstract][Full Text] [Related]
18. Long-term use of intramuscular insulin therapy in a type I diabetic patient with subcutaneous insulin resistance. Brossard JH; Havrankova J; Rioux D; Bertrand S; D'Amour P Diabet Med; 1993 Mar; 10(2):174-6. PubMed ID: 8458196 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Scholtz HE; Pretorius SG; Wessels DH; Becker RH Diabetologia; 2005 Oct; 48(10):1988-95. PubMed ID: 16160867 [TBL] [Abstract][Full Text] [Related]
20. Intramuscular versus subcutaneous injection of unmodified insulin: consequences for blood glucose control in patients with type 1 diabetes mellitus. Vaag A; Pedersen KD; Lauritzen M; Hildebrandt P; Beck-Nielsen H Diabet Med; 1990 May; 7(4):335-42. PubMed ID: 2140087 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]